VarmX

VarmX is a dynamic biotechnology research company dedicated to advancing therapies in the critical fields of hemostasis and thrombosis. With a strong focus on innovation, VarmX is committed to developing and manufacturing therapeutic proteins designed to restore hemostasis effectively and safely. The primary address of VarmX is Middelweg 38B, Leiden, 2312 KJ, NL, with an additional location at Automatikvej 1, Søborg, Capital Region 2860, DK.

VarmX’s lead compound, VMX-C001, represents a significant advancement in addressing bleeding or emergency surgery scenarios for patients on oral factor Xa inhibitors. The company's forward-thinking approach and dedication to addressing unmet medical needs have positioned VarmX as a key player in the biotechnology sector. VarmX continues to build upon its foundation of scientific excellence and strategic investment to drive its programs forward.

As VarmX progresses towards Investigational New Drug (IND) approval and prepares for pivotal trials, the company remains focused on its mission to improve patient outcomes. The team at VarmX is continuously working to enhance its therapeutic offerings and expand its impact on global healthcare. We invite the manager of VarmX to create a customized and exclusive company showcase and product listing on our platform to further amplify its reach and potential.